1.Clinical practice of precision medicine in patients with postoperative refractory recurrent hepatobiliary tumor
Chao CUI ; Bingyang HU ; Tao WAN ; Jushan WU ; Dongdong LIN ; Yu LI ; Linchun FENG ; Baixuan XU ; Guanghai DAI ; Huiyi YE ; Ping XU ; Shichun LU
Chinese Journal of Hepatobiliary Surgery 2019;25(4):241-245
Objective To summarize the preliminary clinical outcomes of combination therapy with molecular targeted agents/immunological agents and to explore the potential value of multidisciplinary therapy in the treatment of postoperative refractory recurrent hepatobiliary tumor.Methods 52 cases of postoperative refractory recurrent hepatobiliary tumor during June 2016 to January 2019 from outpatient and inpatient departments at the First Medical Center of PLA General Hospital were prospectively collected,including 37 males and 15 females,with a mean age of (56.2 ± 8.5) years.Referring to the results of next-generation sequencing (NGS) and other-omics,we designed individualized therapy options for each patient.Follow-ups were done regularly and tumor responses were assessed by modified response evaluation criteria in solid tumors (mRECIST).Results Of 52 patients,median follow-up was 10 months (range 3-31 months).14 (26.9%) patients achieved a complete response (CR).8 (15.3%) patients achieved a partial response (PR).14 (26.9%) patients had stable disease (SD).16 (30.8%,including 4 deaths) had progressive disease (PD).Objective response rate and disease control rate were 42.3% (22/52) and 69.2% (36/52),respectively.The median progression-free survival (PFS) was 7 months.6-and 12-month overall survival rates were 100% (48/48),87.5% (21/24),respectively.Conclusions Precision medicine has good guidance on the treatment of refractory recurrence of hepatobiliary tumors.The combination therapy of multi-target tyrosine kinase inhibitors and immune checkpoint inhibitors may achieve better disease control and deserve further promotion in clinical application.
2.Determination of chloride,sulfate and bicarbonate ions in Compound polyethylene glycol electrolyte powder (Ⅲ) by ion chromatography
Xianhua ZHANG ; Yuxin ZHAO ; Haiyan ZHOU ; Xiaolu ZHU ; Dengyan LAI ; Jiao ZHU ; Tao PENG ; Shichun YE
China Pharmacy 2024;35(22):2769-2772
OBJECTIVE To establish an ion chromatography method for the simultaneous determination of chloride, sulfate and bicarbonate ions in Polyethylene glycol electrolyte powder (Ⅲ). METHODS The chromatographic column was a Dionex IonpacTM AS11-HC anion analysis column, with a Dionex IonPacTM AG11-HC guard column. The mobile phase was 10 mmol/L potassium hydroxide at an isocratic elution flow rate of 1.2 mL/min. The detector was a conductivity detector, and the suppressor was a Dionex AERS with a suppressor current of 30 mA. The column temperature was maintained at 30 ° C, and the injection volume was 10 μL. Chloride and sulfate contents were calculated by external standard method, while bicarbonate content was determined by double logarithmic fitting standard curve method. RESULTS Under these chromatographic conditions, chloride, sulfate and bicarbonate ions were effectively separated with linear ranges of 0.055 to 0.219 mg/mL (r=0.999 9), 0.155 to 0.618 mg/mL (r=1.000 0), and 0.065 to 0.121 mg/mL (r=0.999 9), respectively. The recoveries were 98.06% to 101.34%, 97.37% to 101.25%, and 97.16% to 99.81%, respectively, with RSDs of 1.1%, 1.3% and 1.0% (n=9). The RSDs for the evaluation of precision, accuracy, stability and ruggedness were all less than 2%. CONCLUSIONS The established ion chromatography is simple, rapid, accurate, precise and durable, can simultaneously determine the contents of chloride, sulfate and bicarbonate ions in Polyethylene glycol electrolyte powder (Ⅲ), which is suitable for its quality control.
3.Discussion on the management strategy of patients aged over 70 years with esophageal cancer
YE Jingting ; TANG Shanwei ; TANG Guiwang ; LU Shichun ; SUN Chao ; LV Xiaoxia ; ZOU Hui ; SHU Yusheng
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2018;25(10):895-899
Esophageal cancer (EC) is the eighth dangerous cancer in the world. As the global population ages, the management of elderly patients with EC poses a challenge as they have many aging-associated diseases and physiological changes. In addition, the data on the tolerability of cancer treatment and the use of combined therapies in the patients to guide their treatment are limited. In this paper, we reviewed the literatures and discussed the effect of surgical resection and the potential complications of elderly patients. We reviewed the basic principles of combined therapy and the potential benefits of chemotherapy or chemoradiotherapy for patients and focused on the management of elderly patients with EC as well as the role of comprehensive assessment for aging to provide treatment options for elderly patients.